Phage therapy in the battle towards antibiotic resistance

Kexin Zhang

doi:10.1117/12.2691862

7 September 2023 Phage therapy in the battle towards antibiotic resistance

Kexin Zhang

Proceedings Volume 12789, International Conference on Modern Medicine and Global Health (ICMMGH 2023); 1278908 (2023) https://doi.org/10.1117/12.2691862
Event: International Conference on Modern Medicine and Global Health (ICMMGH 2023), 2023, Oxford, United Kingdom

Abstract

Nowadays, antibiotics has been mainly used to make control of infections due to bacteria. However, bacterium has become more adapted to antibiotics, so the effect of antibiotic therapy seems to have been blunted. Scientists have found another, more suitable antimicrobial agent, that’s phage. Phage is complex, it lowers the risk of infection by having the power to get rid of the bacteria in the patient's body. The discovery of phages goes back a long way, but there have been concerns about their use. To demonstrate the effect of phages on specific bacteria, scientists conducted experiments. The trial was described as multicenter, double-blind and randomized phase 2/1, the both safety and morality are guaranteed. PP1131 or the standard of treatment was randomly assigned (1:1) to patients using a responsive, dynamic web platform and a case report form that is digital. Participants were administered PP1131 or sulfadiazine silver at day 0. The trial lasted for seven days and the period of observation was in 21 days. As a consequence, the initial endpoint was arrived in the PP1131 group in a medium time of 144 hours as opposed to a median time of 47 hours in the group receiving standard medical care. Approximately 50% of the all the participants in the PP1131 group possessed a high bacterial load, compared to 15% in the group providing the standard level of care.

Citation Download Citation

Kexin Zhang "Phage therapy in the battle towards antibiotic resistance", Proc. SPIE 12789, International Conference on Modern Medicine and Global Health (ICMMGH 2023), 1278908 (7 September 2023); https://doi.org/10.1117/12.2691862

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available